325 related articles for article (PubMed ID: 17403783)
1. HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53.
Sasaki T; Gan EC; Wakeham A; Kornbluth S; Mak TW; Okada H
Genes Dev; 2007 Apr; 21(7):848-61. PubMed ID: 17403783
[TBL] [Abstract][Full Text] [Related]
2. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation.
Thomas MC; Chiang CM
Mol Cell; 2005 Jan; 17(2):251-64. PubMed ID: 15664194
[TBL] [Abstract][Full Text] [Related]
3. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
4. DNA damage activates p53 through a phosphorylation-acetylation cascade.
Sakaguchi K; Herrera JE; Saito S; Miki T; Bustin M; Vassilev A; Anderson CW; Appella E
Genes Dev; 1998 Sep; 12(18):2831-41. PubMed ID: 9744860
[TBL] [Abstract][Full Text] [Related]
5. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis.
Tang Y; Luo J; Zhang W; Gu W
Mol Cell; 2006 Dec; 24(6):827-39. PubMed ID: 17189186
[TBL] [Abstract][Full Text] [Related]
6. BAT3 modulates p300-dependent acetylation of p53 and autophagy-related protein 7 (ATG7) during autophagy.
Sebti S; Prébois C; Pérez-Gracia E; Bauvy C; Desmots F; Pirot N; Gongora C; Bach AS; Hubberstey AV; Palissot V; Berchem G; Codogno P; Linares LK; Liaudet-Coopman E; Pattingre S
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4115-20. PubMed ID: 24591579
[TBL] [Abstract][Full Text] [Related]
7. Chromatin remodelling protein SMAR1 inhibits p53 dependent transactivation by regulating acetyl transferase p300.
Sinha S; Malonia SK; Mittal SP; Mathai J; Pal JK; Chattopadhyay S
Int J Biochem Cell Biol; 2012 Jan; 44(1):46-52. PubMed ID: 22074660
[TBL] [Abstract][Full Text] [Related]
8. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation.
Ito A; Kawaguchi Y; Lai CH; Kovacs JJ; Higashimoto Y; Appella E; Yao TP
EMBO J; 2002 Nov; 21(22):6236-45. PubMed ID: 12426395
[TBL] [Abstract][Full Text] [Related]
9. Human T-cell leukemia virus type-1-encoded protein HBZ represses p53 function by inhibiting the acetyltransferase activity of p300/CBP and HBO1.
Wright DG; Marchal C; Hoang K; Ankney JA; Nguyen ST; Rushing AW; Polakowski N; Miotto B; Lemasson I
Oncotarget; 2016 Jan; 7(2):1687-706. PubMed ID: 26625199
[TBL] [Abstract][Full Text] [Related]
10. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.
Shiseki M; Nagashima M; Pedeux RM; Kitahama-Shiseki M; Miura K; Okamura S; Onogi H; Higashimoto Y; Appella E; Yokota J; Harris CC
Cancer Res; 2003 May; 63(10):2373-8. PubMed ID: 12750254
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305.
Wang YH; Tsay YG; Tan BC; Lo WY; Lee SC
J Biol Chem; 2003 Jul; 278(28):25568-76. PubMed ID: 12724314
[TBL] [Abstract][Full Text] [Related]
12. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins.
Kobet E; Zeng X; Zhu Y; Keller D; Lu H
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12547-52. PubMed ID: 11070080
[TBL] [Abstract][Full Text] [Related]
13. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage.
Ianari A; Gallo R; Palma M; Alesse E; Gulino A
J Biol Chem; 2004 Jul; 279(29):30830-5. PubMed ID: 15123636
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription.
Harrod R; Nacsa J; Van Lint C; Hansen J; Karpova T; McNally J; Franchini G
J Biol Chem; 2003 Apr; 278(14):12310-8. PubMed ID: 12501250
[TBL] [Abstract][Full Text] [Related]
15. The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage.
Magrini R; Russo D; Fronza G; Inga A; Menichini P
J Cell Biochem; 2007 Apr; 100(5):1276-87. PubMed ID: 17063487
[TBL] [Abstract][Full Text] [Related]
16. Functional interplay between p53 and E2F through co-activator p300.
Lee CW; Sørensen TS; Shikama N; La Thangue NB
Oncogene; 1998 May; 16(21):2695-710. PubMed ID: 9652736
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of Tip60 by p38α regulates p53-mediated PUMA induction and apoptosis in response to DNA damage.
Xu Y; Liao R; Li N; Xiang R; Sun P
Oncotarget; 2014 Dec; 5(24):12555-72. PubMed ID: 25544752
[TBL] [Abstract][Full Text] [Related]
18. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation.
Jin Y; Zeng SX; Dai MS; Yang XJ; Lu H
J Biol Chem; 2002 Aug; 277(34):30838-43. PubMed ID: 12068014
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets.
Narayanan BA; Narayanan NK; Re GG; Nixon DW
Int J Cancer; 2003 Mar; 104(2):204-12. PubMed ID: 12569576
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region.
Somasundaram K; El-Deiry WS
Oncogene; 1997 Mar; 14(9):1047-57. PubMed ID: 9070653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
